RNase MRP is a site-specific endoribonuclease that processes primer RNA from the leading-strand origin of mammalian mitochondrial DNA replication. It is present in active form as isolated from the nucleus, suggesting a bipartite cellular location and function. The relatively high abundance of nucleus-localized RNase MRP has permitted its purification to near homogeneity and, in turn, has led to the identification of protein components of this ribonucleoprotein. Analysis of the mode of RNA cleavage by nuclear RNase MRP revealed the surprising and unprecedented ability of the endonuclease to process RNA at multiple discrete locations. Substrate cleavage is dependent on the presence of a previously described G-rich sequence element adjacent to the primary site of RNA processing. Downstream cleavages occur in a distance-and sequence-specific manner.
Muhisite processing by nuclear RNase MRP Nuclear Dignam extracts (Dignam et al. 1983) were adsorbed on and eluted from DEAE-Sephacel, concentrated by Centricon centrifugation, and subjected to glycerol gradient sedimentation. Fractions were collected, and aliquots were immunoprecipitated by antiTh sera. The coprecipitated RNAs were 3'-end-labeled and assayed by denaturing gel electrophoresis. Examples of the reproducible RNA profiles obtained using h u m a n or mouse nuclear extracts are shown in Figure 1 , A and C, respectively. Greater than 95% of RNase MRP RNA is routinely immunoprecipitable as judged by RNA hybridization analyses (data not shown). Two peaks of nuMRP RNA were obtained following glycerol gradient sedimentation, nuMRP that sedimented at 20 S, as determined by analysis of U5 small nuclear RNP (snRNP) sedimentation in parallel glycerol gradients, was devoid of full-size RNase P RNA or any smaller RNase P or RNase MRP RNA species ( Fig. 1B and D; data not shown). The second peak of nuMRP RNA cofractionated with RNase P RNA (as well as RNase P activity; see below). In this study we have focused on nuMRP alone. Routinely, fractions 2-4 ( Fig. 1A and C) were pooled, rechromatographed on DEAE-Sephacel, adsorbed twice on anti-mgG/IgG/Sepharose, and concentrated by Centricon centrifugation. The fractions were then centrifuged in a second glycerol gradient; Figure 1 , B and D, depicts the total RNA content of the fractions of two such gradients for h u m a n and mouse nuMRP. Fractions sedimenting at 20 S contained a single RNA species of -2 7 0 nucleotides that hybridized with the respective h u m a n or mouse antisense MRP RNA probe; no RNase MRP RNA was detected in fractions corresponding to the sedimentation of -270-nucleotide RNA alone (data not shown). These data indicate that the eukaryotic nucleus contains a significant amount of full-length RNase MRP RNA, most if not all of which is assembled into anti-Th reactive RNPs. Moreover, this population of nuMRP does not contain any detectable RNase MRP RNA processed (or breakdown) product and is devoid of any RNase P RNA species, as well as any other detectable RNA.
Identification of nu MRP-associated polypeptfdes
Extracts, as well as purified nuMRP preparations depleted of proteins by SDS/guanidium thiocyanate/ phenol-chloroform extraction or SDS-proteinase K treatment, were used as an antigen source for anti-Th immunoprecipitations. No RNAs were found in the precipitates of protein-depleted extracts (data not shown). Whole-cell extracts were prepared, and immunoprecipitations with various sera were carried out. Among other Figure I . Separation of nuMRP RNPs by successive glycerol gradient sedimentation. (A) Human HeLa cell nuclear extract was fractionated by DEAE-Sephacel chromatography, followed by glycerol gradient sedimentation as described in Materials and methods. Aliquots (100 ~1 each) of individual fractions were subjected to anti-Th immunoprecipitation. The coprecipitating RNA was 3'-end-labeled with pCp and analyzed on a 5% polyacrylamide/7 M urea gel. Fractions 2-4 were pooled and further purified by chromatography on DEAE-Sephacel, followed by anti-mgG/IgG/Sepharose, before resedimentation in a second glycerol gradient.
RNase MRP RNA is the -270-nucleotide species present in lanes 2-8. The larger RNA in lanes 6-8 is RNase P H1 RNA. (B) Aliquots {400 ~1 each) of the fractions of the second glycerol gradient were deproteinized, and the total RNA obtained was 3'-end-labeled and analyzed on a denaturing gel. {20 S) The position of U5 snRNP as evidenced by Sm immunoprecipitation of fractions of parallel glycerol gradients (data not shown). Markers (M) were HpaII-digested pBR322 DNA. (C and D) The same purification procedure was applied to mouse nuclear extracts. RNase MRP RNA is the smaller species in these lanes. Mouse RNase P RNA is assumed to be the slightly larger species in C based on reproducible anti-Th precipitation and the presence of RNase P activity in these fractions.
Cold Spring Harbor Laboratory Press on December 18, 2017 -Published by genesdev.cshlp.org Downloaded from lower relative molecular mass species a polypeptide of 40 kD was detected in the anti-Th precipitates from extracts of both [3SS]methionine/[gSS]cysteine and [3H]-leucine-labeled cells (data not shown). To determine whether these proteins copurified with nuMRP activity, human HeLa cells were subjected to pulse-chase labeling with TrangSS-label and nuMRP was purified as described above. Aliquots of every fraction of the second glycerol gradient were RNase A/micrococcal nuclease-treated and analyzed by SDS-polyacrylamide gel electrophoresis followed by fluorography. About 10 polypeptides, ranging between 10 and 100 kD, were found in fraction 2 (Fig.  2) . Most of these polypeptides were located in the fractions containing nuMRP RNA (see Fig. 1B , fraction 2). These proteins, especially the 40-kD species observed consistently in anti-Th immunoprecipitates, are the potential components of nuMRP.
N u M R P processes R N A at multiple sites
Fractions obtained after successive glycerol gradient purifications were assayed for nuMRP activity using the Fraction  2  3  4  5  6  7  8   kDa   46 30 .
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Figure 2. Identification of nuMRP polypeptides. HeLa cells (2 x l0 s) were pulse-chase-labeled with Tran3SS-label. These cells were used for purification of nuMRP as in Fig. 1 . Fractions from the final glycerol gradient were RNase treated, and the proteins were analyzed by SDS-gel electrophoresis and fluorography. (Lane M) The 14C-methylated molecular mass marker proteins: bovine serum albumin, ovalbumin, carboanhydrase, ~-lactoglobulin, and cytochrome c.
standard mouse mitochondrial RNA substrate (Fig. 3) . The decision to utilize this substrate was based on the following facts: (1) It was the substrate of the standard assay that defined the overall reaction conditions for RNase MRP (Chang and Clayton 1987a) ; (2) the exact positions of cleavage by human and mouse mtMRP on the wild-type substrate sequence are documented (Chang and Clayton 1987a, b; Bennett and Clayton 1990) ; (3) series of both deletion and point mutations of this substrate are available and have been characterized with respect to mtMRP cleavage {Bennett and Clayton 1990); and (4) there is no identified nuclear RNA substrate for RNase MRP. Consistent with all previous analyses of mtMRP, nuMRP cleaved 5' to a G-rich sequence block resulting in a 130-nucleotide RNA product (site 1 cleavage). Surprisingly, two additional cleavage events were evident, resulting in products of -9 0 (site 2 cleavage) and -3 0 nucleotides (site 3 cleavage), respectively. High-resolution mapping of site 2 and 3 reaction products indicated that cleavages occurred within a canonical 5'-GNGNA-3' sequence (data not shown). Cleavages at all sites were found to be conserved evolutionarily between human and mouse, because purified mouse nuMRP (Fig.  3A) exhibited the same multiple site specificity as human nuMRP (Fig. 3B ) on the standard mouse RNA substrate.
Individual glycerol gradient fractions were assayed for nuMRP and RNase P activity (Fig. 3A) . Those glycerol gradient fractions that contained both RNase MRP RNA and RNase P RNA {fractions 6-8) contained both RNase MRP and RNase P (as judged by pre-tRNA Tyr cleavage activity). In addition, no pre-tRNA cleavage activity was present in fractions containing RNase MRP alone (fractions 3-5). These data indicate that (1) as expected, the presence of RNase P RNA is required for RNase P activity (Bartkiewicz et al. 1989) , and (2) the presence of H1 RNA in nuMRP-containing fractions does not change the cleavage specificity of nuMRP; no cleavage occurs at any novel sites, nor is the full range of nuMRP cleavage affected by the presence of RNase P.
To investigate further the requirement for nuMRP in the downstream cleavage events, micrococcal nuclease inactivation and immunodepletion experiments were performed. Pooled peak fractions of nuMRP, purified through the second glycerol gradient, were preincubated with micrococcal nuclease or the appropriate controls and assayed for activity (Fig. 4A ). Cleavage at each of the three sites was reduced equivalently with increasing concentrations of micrococcal nuclease in the preincubation step. In complementary experiments nuMRP was preincubated with anti-Th IgG, as well as normal human immunoglobulins, before performing standard activity assays. The data of Figure 4B demonstrate the specific and concentration-dependent depletion of nuMRP activity by anti-Th IgG. Taken together, these results confirm that all endonuclease activities that copurify with nuMRP require an intact and functional nuMRP RNP because the loss of integrity of nuMRP RNA or the depletion of Th antigen inhibits all cleavage activity. A recent mutational analysis demonstrated that efficient site-specific cleavage depends on the interaction of mtMRP with two evolutionarily conserved mitochondrial sequences, conserved sequence blocks II and III (CSBII and CSBIII, respectively) (Bennett and Clayton 1990) . In that study it was shown that an oligonucleotide spanning the CSBII/CSBIII region and, thus, a D N A sequence representation of the RNA substrate, was a potent competitive inhibitor of the cleavage reaction. As demonstrated in Figure 5 , cleavage by nuMRP at all three sites was abolished in a concentration-dependent manner at nanomolar concentrations of the CSBII/CSBIII oligonucleotide. At these concentrations a control oligonucleotide had no detectable effect. The ability of the CSB-II/CSBIII oligonucleotide to inhibit all three cleavage events reinforces the conclusion of the prior micrococcal nuclease and immunodepletion experiments: Functional nuMRP is responsible for or involved in all three cleavage activities on the RNA substrate.
Downstream cleavage is dependent on physical interaction with an upstream G box
A unique feature of nuMRP is that it is involved solitarily in multiple RNA-processing events. To begin to establish the basic reaction of nuMRP with substrate RNA, time course and mutational analyses were carried out. RNA was labeled at either the 3' or 5' end and incubated with various amounts of nuMRP (Fig. 6) . If cleavages at each of the three sites were independent events of similar efficiency, all of the reaction products (depicted in Fig. 3B ) should be apparent regardless of whether the RNA substrate was 3'-or 5'-end-labeled. The 3'-end-labeled substrate yielded three cleavage prod- ucts, indicating that all three cleavage sites were recognized in an independent or, possibly, in a 5' ---> 3' processive fashion. Cleavage of the 5'-end-labeled substrate, however, resulted in the exclusive generation of one radiolabeled product migrating at -1 4 0 nucleotides (Fig. 6 , lanes 7-10), corresponding to cleavage at site 1. No radioactive products of 182 or 240 nucleotides, corresponding to site 2 or 3 cleavage, respectively, were obtained. These data show that the additional cleavages at sites 2 and 3 occurred only on those RNA molecules that had been cleaved previously at site 1. However, these data do not prove that site 1 cleavage per se is a prerequisite for cleavages at sites 2 and 3. Additional experiments were conducted to examine the relationship between the various cleavage products produced by nuMRP. Time course analysis of nuMRP activity showed no delay in the production of site 2 and 3 cleavage products relative to that of site 1 (data not shown). In addition, prolonged incubation of purified site 1 RNA cleavage product with nuMRP resulted in only trace cleavage of the input RNA, which is inconsistent with the amount of site 2 and 3 cleavage products produced in reactions containing the full-length RNA substrate (data not shown). Neither of these experiments supports a model whereby the multiple cleavage activity of nuMRP is due to association and reassociation of various RNA substrates with a single RNP. Multisite processing by nuMRP is likely due to the processive action of a single RNP or the action of multiple nuMRP particles on a single RNA moiety.
As noted, high-resolution mapping studies established that nuMRP site 2 and 3 cleavages occurred at two 5'-GNGNA-3' motifs that were located 40 and 95 nucleotides, respectively, downstream of site 1. We assayed the requirement for any downstream sequence surrounding the additional cleavage sites by employing progressive 3'-deletion RNA substrates (Fig. 7A ). Deletion of CSBII (5'-GGGGGUGGGGGGUUU-3') in substrate &3'4 abolished all processing activity (Fig. 7A , lane 10), suggesting that interaction with the nucleotides contained in this G box is critical for all RNase MRP processing. Surprisingly, more limited deletion of substrate RNA sequence and its replacement with pSP65 vector sequence led to new cleavages within the vector sequence, a portion of which was seen with some, but not all, 3'-deletion mutation RNAs. Close inspection of the pSP65 vector sequence revealed four occurrences of the sequence 5'-GNGNA-3', upon which nuMRP cleavage would potentially give rise to products of 174, 145, 91, and 16 nucleotides (see schematic diagram in Fig. 7A ). Cleavage at the vector site 174 (v174), which encompasses the sequence 5'-GCGUA-3', was seen only with mutation d13'28 ( Fig. 7A , lane 6). Cleavage at site v145 (sequence 5'-GUGAA-3') occurred with mutation A3'28, as well as (much more prominently) with mutation A3'l 5 (Fig. 7A , lanes 6 and 8). No specific cleavages were seen at sites v91 or v16. Essentially the same results were obtained with h u m a n nuMRP {data not shown). Analysis of these additional processing events (active cleavage sites indicated in boldface italics, below) with respect to their distance from site ! revealed that site v174 is located 85, 38, and 25 nucleotides downstream of site 1 in the mutations &3'75, A3'28, and A3'15, respectively; v145 is located 114, 67, and 54 nucleotides downstream of site 1 in those respective mutations. These data indicate that the additional processing by nuMRP depends on the occurrence of a 5'-GNGNA-3' motif; optimal cleavage also requires at least some m i n i m a l spacing between adjacent cleavage sites. Depending on the respective 3'-deletion mutation, an additional cleavage occurred 132-192 nucleotides downstream of site 1, within the sequence 5'-CUGGG-GUGCCUAAUGAGUGAGCU-3'. This sequence contains a truncated version of CSBII and six partially overlapping 5'-GNGNA-3'-motif point mutations [GNGNG, GNGNC, G N G N U ; indicated in boldface italics, above). Cleavage at this site, however, was not conserved between h u m a n and mouse nuMRP (data not shownl. In addition, as opposed to additional processing at all other sites described above, we noted little variability with regard to the extent of cleavage at this location within the various 3'-deletion mutations (Fig. 7A) . Cleavage was strictly dependent on CSBII and abolished upon its deletion (Fig. 7A, lane 101 .
We then asked which nucleotides within the G box are important for nuMRP multisite processing. Point-mutation substrate RNAs were selected that either increased (13C16C; "up mutation"), decreased (13C17C, 14C16C; "down mutation"), or had no effect (17C) on mtMRP cleavage efficiency (see schematic drawing in Fig. 7B and legend for nomenclature) (Bennett and Clayton 1990) . These substrates were incubated with nuMRP and an equal amount of wild-type 5'-end-labeled substrate, the latter serving as an internal control for cleavage efficiency (Fig. 7B) . Similar to mtMRP, CSBII up/down mutations showed an increase/reduction of site 1 cleavage by nuMRP (lanes 6, 8, and 10). Interestingly, mutants 17C, 13C17C, and 14C16C resulted in a concomitant decrease of site 2 and 3 products (lanes 4, 6, and 8, respectively). With mutant 14C16C, which reduced site 1 cleavage 10-fold (and also slightly changed the exact cleavage site), cleavage products of sites 2 and 3 were reduced to almost background level (lane 8). Combined with the time course data (Fig. 6 ), the results with the mutated substrate RNAs show that the competence of nuMRP for additional downstream RNA processing is Figure 6 . nuMRP cleavage at additional downstream sites is preceded by upstream cleavage at the G-rich sequence block. The mode of mouse nuMRP cleavage was analyzed by employing the mouse RNA substrate labeled at the 3' end (leftl or 5' end (right), respectively. Increasing amounts of nuMRP (0, 1, 2, 4, 8, 0, 0.5, 1, 1.5, and 2 ng; lanes 1-10, respectively) were tested in standard RNase MRP cleavage assays. dependent on physical interaction (binding and/or cleavage) with a G box embedded within CSBII. Point mutations in CSBIII have been shown previously to inhibit cleavage at site 1 by mtMRP (Bennett and Clayton 1990 ). The effect of CSBIII point mutations on the multiple cleavage activity of nuMRP was examined, using 3'-end-labeled point-mutated substrate in a standard nuMRP cleavage assay (Fig. 7C) . As seen previously with mtMRP, mutations 33C34C and 41G42C (see Fig.  7B and legend for nomenclature) exhibited no cleavage at site 1 (lanes 5 and 8) . In contrast to point mutations in CSBII, no inhibition was found in site 2 or 3 cleavage (cf. Fig. 7C , lanes 5 and 8 with Fig. 7B, lanes 4, 6, and 8) . The specific absence of site 1 cleavage in these mutant RNAs was verified using 5'-end-labeled substrates; again, only site 2 and 3 cleavage products were observed (data not shown). Cleavages at sites 2 and 3, however, were still dependent on nuMRP activity, as the CSBII/CSBIII oligonucleotide specifically inhibited these cleavage events (lanes 3, 6, and 9). Therefore, additional RNA processing by nuMRP is not strictly dependent on cleavage at site 1 but requires the previous or concomitant binding/interaction of nuMRP RNP with the G-rich sequence block CSBII. In short, the G box must be present and recognized for any cleavages to occur, and processing at site 1 precedes downstream cleavages in RNA substrates that permit hydrolysis at site 1. In addition, these results indicate that any substrate RNA refolding that might occur after site 1 cleavage is not a prerequisite for site 2 and 3 cleavages.
Discussion
Th antigenicity of nuMRP: Th40, a molecular link between RNase MRP and RNase P?
Upon sedimentation through glycerol gradients, nuMRP is resolved into two peaks of similar activity. Fractions at 20 S contain nuMRP and, upon further purification, no other RNA. In addition, some nuMRP copurifies with RNase P activity. Because of increasing amounts of various RNase MRP RNA and RNase P RNA fragments in fractions of lower sedimentation values, we have been unable to determine whether or not RNase P can be separated from nuMRP by our purification procedure. Moreover, employing the standard RNase MRP substrate, RNase P RNA-containing fractions of nuMRP yield an identical cleavage pattern to that produced by nuMRP alone. This suggests that if RNase P is able to cleave this substrate, processing does not occur at other sites not cleaved by nuMRP.
Upon sequence comparison of RNase MRP and RNase P RNAs it was noted that the two share some limited stretches of similarity ). Similar to the situation with U-series snRNPs, these RNAs may represent binding sites for related proteins (for review, see Mattaj 1989 ). It appears likely that any such related (evolutionarily conserved) proteins are part of the structure that triggers the anti-Th autoimmune response. A number of nuMRP polypeptides are potential candidates for both binding to MRP RNA and contributing to the Th Multisite processing by nuclear RNase MRP autoimmune response, as they are found both in highly purified nuMRP and in Th immunoprecipitates.
It has been reported that antibodies raised against the Escherichia coli C5 protein (the protein component of bacterial RNase P) cross-react with a 40-kD protein of partially purified human RNase P; this antibody coprecipitated both RNase P H1 and MRP RNAs (Mamula et al. 1989 ). It appears likely that this 40-kD RNase P protein is related (or identical) to Th40, the major Th autoantigen. Th40 may bind to at least one of the four sequence blocks conserved between MRP and HI RNAs and facilitate the coprecipitation of MRP/H1 RNPs from crude cell extracts. One of these sites is related to the C5 protein-binding site on M1 RNA of E. coli RNase P ).
Multisite RNA processing by an RNP
Using our standard RNA substrate, as well as various deletion and point-mutational derivatives, we have begun to understand the basic processing mechanism of mammalian nuMRP. Cleavage by nuMRP occurs within 5'-GNGNA-3' sequence motifs that are spaced at -50-nucleotide intervals; we note that not all possibilities for N have been assayed directly, but this motif is the simplest current possibility. Processing at each site on the RNA substrate requires previous or concurrent interaction of nuMRP with the G-rich sequence block; deletion and point mutations within it eliminate or reduce all cleavage activity. At least two possibilities could account for the observed phenomena (Fig. 8) .
In the first model (Fig. 8, left) , nuMRP is capable of 5' ~ 3' scanning of an RNA molecule. In this model initial loading of nuMRP onto substrate RNA requires the presence of the G-rich sequence block. Following binding of nuMRP to the G box, RNA is cleaved at site 1 and nuMRP migrates down the substrate RNA restricted in its step size by its molecular dimensions. If nuMRP encounters a 5'-GNGNA-3' sequence, cleavage occurs and scanning continues.
It is interesting to note that the cleavage efficiency for downstream 5'-GNGNA-3' motifs, as determined by the 3'-deletion-mutated RNAs, varies slightly between human and mouse nuMRPs. The optimal average spacing for cleavage at 5'-GNGNA-3' is 46 or 56 nucleotides for human or mouse nuMRP, respectively. The human and mouse nuMRP RNAs differ in length by 9 nucleotides. Although such a coincidence could be entirely fortuitous, it may reflect part of the molecular dimensions of the RNP involved in a scanning-type mechanism.
In the second model (Fig. 8, right) , binding of nuMRP at site 1 initiates a nucleation event for progressive nuMRP multimer formation. Upon initial nuMRP binding at the G box, complex formation with another nuMRP molecule takes place such that the catalytic center of the latter becomes positioned -50 nucleotides downstream of site 1. Binding of a downstream nuMRP moiety allows a subsequent RNP to bind, and multimer formation proceeds. If a 5'-GNGNA-3' sequence motif is present within a region of sequence that can be recog- We realize that our present mutational and time course analyses are unable to differentiate between the two models described above. Experiments designed to test directly the necessity of sequential site cleavage (1 > 2 > 3) and enzyme processivity are currently being conducted.
The generation of multiple ordered and specific cleavages by a single RNP enzyme is both unique and intriguing. Although this RNP has only one RNA component, its protein composition is likely complex. This situation is reminiscent of the 20 S U5 snRNP which, in addition to U5 RNA, appears to contain 13 different polypeptides and may be involved in both steps of the splicing reaction {Bach et al. 1989; W i n k e l m a n n et al. 1989). The function of such RNPs may rely on their associated proteins, rather than the RNA, and we anticipate that the full spectrum of cellular RNase MRP function m a y depend on a large complement of protein components. Consistent with this notion, cellular RNA isolates as well as in vitro-synthesized MRP RNA have thus far failed to be catalytic in vitro (Topper and Clayton 1990b; R. Karwan and D.A. Clayton, unpubl.1. On the basis of in vitro complementation assays, a h u m a n protein factor, ASF/SF2, has recently been identified that influences 5'-splice site selection in prem R N A splicing (Ge and Manley 1990; Krainer et al. 19901. Similarly, RNase MRP processing in the nucleus and mitochondria may depend on a different array of protein components. Multisite processing may occur with mtMRP in vivo and depend on one or more protein factor(s) easily dissociable from the enzyme; however, to date, the ability of mtMRP to cleave at any additional sites remains to be proved conclusively. It is clear that at least some preparations of mtMRP cleave only at site 1 (Chang and Clayton 1987a, b; Bennett and Clayton 1990) . Mitochondrial import of RNase MRP is likely to be dif-ferent from the protein import pathway (Hartl and Neupert 1989) . It is possible that regulatory RNase MRP protein factors, which may use the general protein import pathway independently, associate with mtMRP only transiently and are therefore not present in mtMRP isolates, which are subjected to an extensive purification protocol that begins with isolation of mitochondria. Multisite processing by nuMRP provides a complementation assay with which MRP-associated polypeptides might be identified biochemically, thereby suggesting a strategy to investigate the important and interesting question of whether nuMRP and mtMRP are distinct at the level of RNA-processing potential.
The likelihood and possible physiological significance of multisite processing in mitochondria are heightened by comparison of the sites of nuMRP cleavage with the previously mapped mouse mitochondrial RNA to DNA transition sites . Reminiscent of site 1 cleavage, cleavage at site 2 (nucleotide 16,061 of the mouse mitochondrial DNA sequence; Bibb et al. 1981) maps very near an in vivo RNA-DNA boundary (located at nucleotide 16,057). Concomitant cleavages at sites 1 and 2 could provide a small RNA primer for DNA replication. Site 3 cleavage occurs at the downstream boundary of the major origin of mouse leading-strand mitochondrial DNA replication.
Is nuMRP involved in nuclear rRNA processing?
The coisolation of the bulk of RNase MRP activity with the nuclear fraction strongly suggests that nuMRP is involved in nuclear RNA processing. Furthermore, identification of the major Th autoantigen, Th40, as an associated component of nuMRP and the strong nucleolar immunofluorescence produced by Th antisera may imply that nuMRP functions in certain aspects of ribosomal biogenesis, such as rRNA processing. Recently, it has been found that the abundant nucleolar U3 snRNP is involved in the first step of mammalian pre-rRNA processing: specifically, cleavage at the ETS sites and production of stable 45S pre-rRNA precursor (Kass et al. 1990 ). The processing sites have not been mapped at the nucleotide level, and the involvement of other nucleolar snRNPs has not been excluded. Th antisera, however, do not affect processing in these S100 extracts.
Abundant G-rich sequence elements are present in eukaryotic rDNA sequences; however, there are no sequences with significant similarity to CSBIII. Point mutations in CSBIII inhibit cleavage by nuMRP at site 1, adjacent to the G-rich sequence block, but do not affect processing at downstream sites 2 and 3 (see Fig. 7C ). Hence, nuMRP may cleave exclusively in the downstream 5'-GNGNA-3' sequences of potential nuclear pre-rRNA substrates. A G-rich sequence block in a nuclear RNA substrate could provide the initial binding site for nuMRP interaction (see Fig. 8) ; and in the absence of an upstream CSBIII-like element, catalysis would be limited to properly spaced 3'-cleavage motifs. We note that 5'-GNGNA-3' boxes, as well as a G box, are present 3' to the in vivo-mapped ETS processing sites in a conserved region of both human and mouse pre-rRNAs . These downstream regions were found to be important for efficient processing at the upstream ETS sites in vitro ). It will be of value to test whether or not nuMRP is involved in any of the processing reactions at these sites.
Materials and methods
Cell growth
Mouse LA9 or human HeLa cells were grown in suspension in minimum essential medium (MEM, Joklik modified; GIBCO) supplemented with glutamine, nonessential amino acids, penicillin/streptomycin, and 10% calf serum. Cells were split every 24 hr by diluting 1 volume of the cell culture with 2 volumes of medium. Cell density was kept between 4 x l0 s to 5 x 10S/ml (LA9 cells) and 2 x l0 s to 3 x 10Sml (HeLa cells).
Purification of nuMRP
Nuclear extracts, prepared as described by Dignam et al. (1983) , were the source for the purification of nuMRP. These extracts contain only a very minor portion of mitochondrial activities as judged by a specific tRNA assay (Topper and Clayton 1990a) . All purification steps were carried out at 0-4°C. All buffers were treated with 0.2% diethylpyrocarbonate (by stirring for 30 min), autoclaved, and [with the exception of PBS (0.8% NaC1, 0.02% KC1, 10 mM Na2HPO4, 1.7 mM KH2PO4) ] supplemented, just before use, with dithiothreitol (1 mM) and 0.01 volume of 100x protease inhibitor stock. The 100 x protease inhibitor stock was made by dissolving 10 mg of chymostatin, 1.5 mg of leupeptin, 7 mg of pepstatin A, 850 mg of phenylmethylsulfonyl fluoride, 500 mg of benzamidine, and 5 mg of aprotinin in 50 ml of ethanol by stirring overnight. The solution was sterilized by microfiltration and kept at room temperature.
Cells (2 x l0 s to 20 x l0 s) were harvested by centrifugation in a Beckman JA-10 rotor for 6 min at 2500 rpm, washed two to three times with PBS, and transferred to a sterile screwcap plastic tube for the final washes, which were done in a GLC-1 centrifuge for 5 min at 2000 rpm. Washed cells were resuspended in 5-10 cell volumes of RSB (10 mM HEPES-KOH at pH 7.5, 1.5 mM MgC12, 10 mM KC1) and swollen by incubation on ice, with several gentle inversions, for 10 min. Cells were reharvested by centrifugation in the GLC-1 centrifuge and resuspended in 2 cell volumes of RSB. This suspension was then transferred to a Kontes Dounce homogenizer and lysed by 15 strokes with a B pestle; nuclei were harvested by centrifugation ( 10 min at 2500 rpm in a GLC-1 centrifuge). The supernatant was aspirated, and the nuclei were resuspended in 2 cell volumes of extraction buffer (20 mM HEPES-KOH at pH 7.5, 400 mM KC1, 1.5 mM MgC12, 10% glycerol, 0.2 mM EDTA).
Extraction (15 min) was achieved by vortexing for 10 sec at full speed, followed by 5-min incubations on ice. The tubes were then shaken gently for an additional 15 min, end over end, before centrifugation for 5 min (GLC-1 centrifuge at 2500 rpm). The supematant was transferred to 1.5-ml microcentrifuge tubes and cleared by centrifugation for 16 rain at 16,000 rpm in a JA-18.1 rotor. Nuclear extract was dialyzed against that volume of buffer D (20 mM HEPES-KOH at pH 7.5, 1.5 mM MgC12, 0.2 mM EDTA, 10% glycerol), which, at equilibrium (after 3 hr of dialysis), resulted in a KC1 concentration of 150 mM.
The dialysate was cleared by centrifugation in microcentrifuge tubes as described above and applied batchwise to DEAE-Cold Spring Harbor Laboratory Press on December 18, 2017 -Published by genesdev.cshlp.org Downloaded from Sephacel, which was pre-equilibrated with 150 mM KC1 in buffer D (2 mg of protein/ml column volume) in 15-ml screwcap tubes. The tubes were shaken end over end for 15 min each. After centrifugation (1 min in a GLC-1 centrifuge at 2000 rpm), the supernatant was aspirated and the resin was washed twice by shaking for 5 min each with 150 mM KCI in buffer D.
MRP RNP was eluted with 2 column volumes of 250 mM KC1 in buffer D. The eluate was concentrated in Centricon C10 tubes by centrifugation for 8 hr at 8000 rpm (JA-20 rotor). The concentrate was diluted to 1 ml with 150 mM KC1 in buffer D and concentrated in Centricon C100 tubes for 1-2 hr at 4000 rpm . Of this, 50-100 jzl (500 ~g-2 mg of protein) was loaded onto 15-30% glycerol gradients [150 mM KC1 in buffer D (minus glycerol)] and centrifuged for 24 hr at 40,000 rpm in an SW41Ti rotor. Fractions were collected, and aliquots (100-500 ~1) were subjected to anti-Th immunoprecipitation analysis while the remainder were frozen in liquid nitrogen and stored at -80°C. Those fractions, which contained nuMRP but no RNase P RNA, were thawed, pooled, and purified by DEAESephacel chromatography as described above. The eluate was incubated by shaking end over end with anti-m3G/IgG/protein A/Sepharose (1 ml of DEAE eluate/0.4 ml column volume) in a microcentrifuge tube for 30 min.
After centrifugation (2 rain in a microcentrifuge), the supernatant was removed and adsorbed to another anti-m3G/IgG/ protein A/Sepharose batch column as described above. The resuiting supernatant was then centrifuged for 16 min at 16,000 rpm [JA-18.1 rotor) and, thereafter, concentrated in Centricon C100 tubes for 2-4 hr as described above. Fifty microliters of concentrate was diluted with 50 ~.1 of buffer D (containing 5 ~g of bovine serum albumin and 150 mM KC1) and applied to glycerol gradient centrifugation as described above, except that the gradient buffers contained 0.05 mg/ml of bovine serum albumin. Fractions were collected as described above, aliquoted, frozen in liquid nitrogen, and kept at -80°C.
For RNA, protein, and activity assays, fractions were thawed quickly in a 20°C water bath and refrozen in liquid nitrogen immediately after use. This procedure did not change the MRP immunoprecipitability or activity when repeated three times. These highly purified nuMRP fractions did not show any alteration in specific activity after 6 months of storage at -80°C.
In vivo labeling of HeLa cells
All manipulations were carried out under sterile conditions (laminar flow), and all solutions were prewarmed to 37°C. HeLa cells were grown in suspension in MEM (Joklik modified) to a cell density of 2 x 10S/ml. Cells (2 x 10 s) were harvested by centrifugation (6 min at 2500 rpm and 37°C, in a JA-10 rotor), washed three times with MEM without cysteine and methionine or without leucine for labeling with Tran3SS-label or [3H]leucine, respectively. The cells were resuspended in 20 ml of the appropriate media (10 z cells/ml), and 10 ml of each cell suspension was transferred to a petri dish and incubated for 30 rain at 37°C. Afterwards, 5 mCi Tran3SS-label or [3H]leucine (supplemented with the respective nonradioactive amino acids to yield asp. act. of 20 mCi/mmole) was added and incubation was continued at 37°C for 8 hr.
For pulse-chase labeling of HeLa cells, the same protocol was used except that such labeling with Tran3SS-label (1000 Ci/ mmole) was done for 30 min at 37°C. Subsequently, the cells were transferred to a 250-ml spinner flask and diluted with MEM to 4 x 10S/ml. Cell growth was then continued for another 8-14 hr at 37°C, which resulted in a final yield of -2 x 108 labeled cells.
Preparation of total HeLa cell extracts
All steps were carried out at 0-4°C. Cells (2 x 108) were harvested by centrifugation for 5 min at 2000 rpm (GLC-1). After three washes with PBS, the cell suspension was transferred to a sterile 15-ml screwcap plastic tube, resuspended in 10 cell volumes of RSB, and swollen on ice for 10 min (with several gentle inversions). After collection of the cells by centrifugation as described above, the supernatant was aspirated. Twenty cell volumes of RIPA u buffer (50 mM HEPES-KOH at pH 7.5, 400 mM NaC1, 15 mM MgCI~, 10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM DTT, and lx protease inhibitor stock) were added, and extraction was carried out by vortexing full speed for 10 sec every 5 min for 15 min. The lysate was then cleared twice by centrifugation in microcentrifuge tubes for 16 min at 16,000 rpm (JA-18.1 rotor). The supernatants were pooled, aliquoted, frozen in liquid nitrogen, and kept for up to 3 months at -80°C (without intermediate thawing) before immunoprecipitation analysis.
Imm unoprecipi ta tions
Of 90 sera with positive nucleolar staining (Reimer et al. 1988 ), 8 patient sera specifically coprecipitated both H1 and MRP RNAs [the RNA components of human RNase P (Bartkiewicz et al. 1989 ) and RNase MRP, respectively], as evidenced by RNA protection and primer extension analysis (data not shown). No serum was found that precipitated either one of these RNAs exclusively, suggesting that the two RNP enzymes share at least one common epitope .
For the analysis of coprecipitating RNAs, immunoprecipitation was carried out as described (Karwan and Kindas-Mfiegge 1989} . For the analysis of both RNA (after [32p] pCp labeling) and radiolabeled proteins from the same immunoprecipitation reaction, the following method was used. All procedures were done in microcentrifuge tubes at 0--4°C (except when stated otherwise). All buffers were treated with 0.2% diethylpyrocarbonate and autoclaved. Each washing cycle (for one tube) consisted of (1) addition of 800 ~1 of IPBG (20 mM HEPES--KOH at pH 7.5, 500 mM KC1, 0.1% NP-40, 0.25% gelatin, 1 x protease inhibitor stock); (2) 10-sec vortexing at full speed; (3) 10-sec centrifugation in a microcentrifuge tube at room temperature; and (4) quantitative vacuum aspiration of the supernatants.
Preblocking Twenty microliters of a 50% (wt/vol) suspension of protein A-Sepharose (Pharmacia) in PBS (containing 0.1% sodium azide for storage at 4°C) was employed per reaction. Total cell extract (0.5-1 ml from 1 x 107 to 2 x 10 z mocktreated, nonradioactive cells) or a 0.5-ml glycerol gradient fraction was incubated with the protein A-Sepharose beads for 1 hr by slow end-over-end rotation. After centrifugation for 1 rain and aspiration, the pellet (PAS) was kept on ice for up to several hours.
Preclearing Pansorbin (500-1000 ~1 of a 10% suspension, Calbiochem) was transferred to another microcentrifuge tube, washed twice with IPBG by resuspension with a micropipette and centrifugation for 1 min, and coupled to 5 ~1 of rabbit control serum by mixing for 30 rain at room temperature. After two washes with IPBG, 0.5-1 ml of 3sS/3H-radiolabeled extract (from 1 x 107 to 2 x 10 z cells) was added to the Pansorbin-IgG and rotated end over end for 1 hr. The suspension was subsequently centrifuged for 3 rain, and the supernatant was transferred to a fresh tube and centrifuged for another 3 min.
Immunoprecipitation The precleared extract was added to a fresh tube containing 50 ~1 of 10% bovine serum albumin and 2 ~1 of human autoimmune serum. End-over-end rotation was carried out for 1 hr. This solution was then added to the PAS tubes and rotated for 1 hr before centrifugation for 10 sec. An aliquot of the supernatant was frozen in liquid nitrogen and kept as a control at -80°C. The residual supernatant was aspirated.
Washing The PAS--immunocomplex pellet was resuspended in 300 ~1 of IPBG. This slurry was overlaid onto 800 ~zl of 1 M sucrose (in IPBG) in a fresh tube and centrifuged for 1 min. The supernatant was aspirated to the interface. Two hundred microliters of 2 M urea (in IPBG) was overlaid, and aspiration (down to the pellets) was carried out immediately. The pellet was then washed seven times with IPBG and once with PBS.
Extraction and purification of protein and RNA One hundred microliters of guanidium mix (prepared according to Maniatis et al. 1982) and 100 ~zl of phenol were added to the washed pellet and vortexed, and incubation was carried out at 65°C for 5 min. After cooling to room temperature, 100 ~1 of chloroform was added. Extraction was carried out by mixing for 5 min. The aqueous phase was re-extracted once with chloroform, and the organic phase was re-extracted once with 150 ~1 of water. Proteins were precipitated, purified, and analyzed on SDS gels as described (Karwan and Kindfis-Mfiegge 1989) . Fluorography was done with Enlightning according to the recommendations of the supplier (NEN). Gels were exposed with two screens for 3 days to 3 months. The RNA was precipitated overnight with ethanol/0.3 M sodium acetate and collected by centrifugation for 20 rain. After washing once with 70% ethanol, the RNA was 3'-end-labeled using 10 ~Ci of 5'-[32p]pCp (3000 Ci/mmole) in 50 mM HEPES-KOH {pH 7.5), 10 mM MgC12, 3 mM dithiothreitol, 3 ~M ATP, 0.5 U/ml of RNAguard (Pharmacia), and 0.05 U/ml of T4 RNA ligase (Pharmacia). Incubation was on ice for 12-18 hr. RNA was purified by three rounds of precipitation with ethanol/2.5 M ammonium acetate in the presence of 10 ~g of tRNA carrier, redissolved in 10 mM EDTA (pH 8.0), 90% formamide, and 6.4% glycerol, boiled for 10 min, chilled on ice, separated on 5% polyacrylamide/7 M urea gels, dried, and analyzed by autoradioagraphy. Exposure (with screen) was for 12 hr to 2 weeks.
Preparation of substrate RNAs
Plasmid DNAs (50 ~g each) were digested overnight with the appropriate restriction enzyme and purified by phenol-chloroform extraction and ethanol-sodium acetate precipitation. The following DNA templates (2-10 ~g each) were used for in vitro transcription reactions with SP6 RNA polymerase according to Sambrook et al. ( 1989) : FokI-digested pUC 19: :TyrT containing pre-tRNA Tyr (Guerrier-Takada et al. 1988) ; XbaI-digested pMR718B (Chang and Clayton 1987a ); PvuII-digested 3'-deletion mutations A3'75, &3'53, 53'28, 53'15, and 53'4 (Bennett and Clayton 1990) ; and XbaI-digested point mutations pMS17C, pMSI3C16C, pMS13C17C, pMS14CI6C, pMS33-C34C, and pMS41G42C (Bennett and Clayton 1990) . 5'-and 3'-End labelings were done as described previously (Bennett and Clayton 1990 ). All labeled transcripts were purified by denaturing get electrophoresis as described previously (Chang and Clayton 1987a) .
nuMRP and RNase P cleavage assays nuMRP cleavage reactions were carried out according to Chang and Clayton {1987a), except that 5000 cpm of substrate RNA Multisite processing by nuclear RNase MRP and 1 unit of RNAguard were used per reaction. RNase P cleavage reactions were carried out according to Guerrier-Takada et al. (1988) .
Miscellaneous
Anti-m3G/protein A/Sepharose was made by the coupling of mouse monoclonal anti-mgG antibodies to protein A-Sepharose (Pharmacia) using dimethylpimelimidate (Sigma) as described by Harlow and Lane (1988) . High-resolution mapping of nuMRP cleavage sites was carried out as described by Chang and Clayton (1987a) . Protein concentrations were estimated according to Bradford { 1976) .
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